			OCT 29 2007	0 4 5	
) 3 \$\f\$\text{\cong}\con	APPLICATION NO.: 10/789,051	ATTY. DOCKET NO.: C1039.70083US06
			BYRADENARIS	FILING DATE: February 26, 2004	CONFIRMATION NO.: 8295
				APPLICANT: Krieg et al.	
				CROUD ART INIT. 1646	
Sheet	1	of	3	GROUP ART UNIT: 1645 EXAMINER: O. Ogunbiyi	

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Doct		Name of Patentee or Applicant of Cited	Date of Publication or Issue	
Initials #	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY	
		5,658,891		Draper et al.	08-19-1997	
		5,665,580		Crooke et al.	09-09-1997	
•		5,681,944		Crooke et al.	10-28-1997	
***		5,843,770		Ill et al.	12-01-1998	
		5,854,418		Chang et al.	12-29-1998	
		5,858,987		Beer-Romero et al.	01-12-1999	
		5,985,662		Anderson et al.	11-16-1999	
		6,107,062		Hu et al.	08-22-2000	
		6,114,167		Symonds et al.	09-05-2000	
		7,157,437	B2	Van Nest	01-02-2007	
		2006-0264391	A1	Van Nest	11-23-2006	
		2007-0037767	A1	Bratzler et al.	02-15-2007	
<u>-</u> -		2007-0065467	A1	Krieg et al.	03-22-2007	
		2007-0066553	Al	Krieg et al.	03-22-2007	
		2007-0066554	Al	Krieg et al.	03-22-2007	
-		2007-0078104	A1	Krieg et al.	04-05-2007	
		2007-0129320	A9	Davis et al.	06-07-2007	
		2007-0142315	Al	Forsbach et al.	06-21-2007	
		2007-0184465	A1	Wagner et al.	08-09-2007	
		2007-0202128	A1	Krieg et al.	08-30-2007	
		2007-0224210	A1	Krieg et al.	09-27-2007	
		2007-0232622	Al	Lipford et al.	10-04-2007	
		2007-0129320	A9	Davis et al.	06-07-2007	
		2007-0142315	A1	Forsbach et al.	06-21-2007	
		2007-0184465	A 1	Wagner et al.	08-09-2007	
		2007-0202128	Al	Krieg et al.	08-30-2007	
		2007-0224210	A1	Krieg et al.	09-27-2007	
		2007-0232622	A1	Lipford et al.	10-04-2007	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO)-1449/A and B (m	nodifie	1 PTO/SB/08)	APPLICATION NO.: 10/789,051	ATTY. DOCKET NO.: C1039.70083US06
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				FILING DATE: February 26, 2004 CONFIRMATION NO.: 8295	
	STATEMENT BY APPLICANT			APPLICANT: Krieg et al.	
Sheet 2 of 3		GROUP ART UNIT: 1645	EXAMINER: O. Ogunbiyi		

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	Fore	eign Patent Docur	nent	Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		BRANDA et al., B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1. Clin Immunol Immunopathol. 1996 May;79(2):115-21.	
		JACOBSON et al., Early viral response and on treatment response to CpG 10101 (ACTILON TM), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 57 th Annual Meeting of American Association for the Study of the Liver Diseases (AASLD). 2006 Oct 30, Boston, Massachusetts; Presented Abstract #96.	
		McHUTCHISON et al., Early viral response to CpG 10101, in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response. 41 st Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 26-30, Vienna, Austria; Submitted Abstract.	!
		McHUTCHISON et al., Final results of a multi-center phase 1B, randomized, placebo-controlled, dose-escalation trial of CpG 10101 in patients with chronic hepatitis C virus. 41 st Annual Meeting of European Association for the Study of the Liver (EASL). 2006 April 30, Vienna, Austria; Presented Abstract #111.	
		McHUTCHISON et al., Early clinical results with CpG 10101, a new investigational antiviral TLR9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus. 12 th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). 2006 July 3, Paris, France; Presented Abstract #O105.	
		YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese.	Yes
	*	Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned).	
	*	Patent Interference No. 105,526 Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007.	
	*	Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/789,051	ATTY. DOCKET NO.: C1039.70083US06
	`		,	FILING DATE: February 26, 2004 CONFIRMATION NO.: 8295	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1645	EXAMINER: O. Ogunbiyi		
Sheet	3	of	3		

	*	Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. §	
		112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-	
		Fact). (Electronically filed, unsigned). June 18, 2007.	
		Patent Interference No. 105,526 Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art	
		Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as	
,		Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.	
	*	Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz	
		Parent Application) (Electronically filed, unsigned) July 25, 2007.	
	*	Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58)	
	L	(Electronically filed, unsigned) July 25, 2007.	
	*	Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement	\neg
		and Written Description) (Electronically filed, unsigned) September 10, 2007.	
	*	Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed,	
		unsigned) September 10, 2007.	
	*	Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed,	
		unsiged) September 10, 2007.	
l i	*	Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims	
		46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.	
		Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive	
		Motion 6) (Electronically filed, unsigned) September 10, 2007.	
	*	Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1)	
		(Electronically filed, unsigned) September 10, 2007.	
	*	Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2)	
		(Electronically filed, unsigned) September 10, 2007.	
}	*	Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion	
	ļ	to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.	
	*	Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007	
	*	Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007	
	*	Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007	
	*	Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007	
	*	Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007	
	*	Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007	
	*	Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007	
	*	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007	

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/690,495, filed October 21, 2003, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.